Prestige Consumer Healthcare (PBH) Change in Receivables (2010 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Change in Receivables of -$495000.0 for Q4 2025, down 107.84% year-over-year from $6.3 million in Q4 2024, and down 101.65% quarter-over-quarter from $29.9 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Change in Receivables (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Change in Receivables history runs 16 years deep, the most recent figure standing at -$495000.0 for Q4 2025.
- In Q4 2025, Change in Receivables fell 107.84% year-over-year to -$495000.0; the TTM figure through Dec 2025 stood at $27.3 million (up 385.15% YoY), while the FY2025 annual figure was $16.3 million, up 158.26% from the prior year.
- Change in Receivables for Q4 2025 stood at -$495000.0, down from $29.9 million in the prior quarter.
- The five-year high for Change in Receivables was $29.9 million in Q3 2025, with the low at -$27.3 million in Q2 2025.
- The 5-year median for Change in Receivables is $2.0 million (2022), against an average of $3.7 million.
- The sharpest annual moves came in 2024 and 2025: Change in Receivables slumped 824.98% in 2024, then surged 3726.04% in 2025.
- Prestige Consumer Healthcare's Change in Receivables stood at -$12.5 million in 2021, then soared by 170.56% to $8.8 million in 2022, then increased by 29.88% to $11.4 million in 2023, then sank by 44.74% to $6.3 million in 2024, then tumbled by 107.84% to -$495000.0 in 2025.
- Business Quant data shows PBH's Change in Receivables at -$495000.0 in Q4 2025, $29.9 million in Q3 2025, and -$27.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.46 Bn | 2.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -495,000.00 |
| Dec 31, 2025 | -495,000.00 |
| Sep 30, 2025 | 29.92 Mn |
| Sep 30, 2025 | 29.92 Mn |
| Jun 30, 2025 | -27.34 Mn |
| Jun 30, 2025 | -27.34 Mn |
| Mar 31, 2025 | 25.20 Mn |
| Mar 31, 2025 | 25.20 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Dec 31, 2024 | 6.32 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Jun 30, 2024 | -6.37 Mn |
| Jun 30, 2024 | -6.37 Mn |
| Mar 31, 2024 | -695,000.00 |
| Mar 31, 2024 | -695,000.00 |
| Dec 31, 2023 | 11.43 Mn |
| Dec 31, 2023 | 11.43 Mn |
| Sep 30, 2023 | 1.22 Mn |
| Sep 30, 2023 | 1.22 Mn |